BR9806793A - Processos e composições de fator tissular para coagulação e tratamento de tumores. - Google Patents

Processos e composições de fator tissular para coagulação e tratamento de tumores.

Info

Publication number
BR9806793A
BR9806793A BR9806793-1A BR9806793A BR9806793A BR 9806793 A BR9806793 A BR 9806793A BR 9806793 A BR9806793 A BR 9806793A BR 9806793 A BR9806793 A BR 9806793A
Authority
BR
Brazil
Prior art keywords
compositions
tissue factor
coagulation
treatment
tumors
Prior art date
Application number
BR9806793-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Philip E Thorpe
Steven W King
Boning Gao
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR9806793A publication Critical patent/BR9806793A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR9806793-1A 1997-01-22 1998-01-20 Processos e composições de fator tissular para coagulação e tratamento de tumores. BR9806793A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3592097P 1997-01-22 1997-01-22
US3620597P 1997-01-27 1997-01-27
US4242797P 1997-03-27 1997-03-27
PCT/US1998/001012 WO1998031394A2 (en) 1997-01-22 1998-01-20 Tissue factor methods and compositions for coagulation and tumor treatment

Publications (1)

Publication Number Publication Date
BR9806793A true BR9806793A (pt) 2000-05-16

Family

ID=27364921

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9806793-1A BR9806793A (pt) 1997-01-22 1998-01-20 Processos e composições de fator tissular para coagulação e tratamento de tumores.

Country Status (17)

Country Link
US (5) US6132730A (cg-RX-API-DMAC7.html)
EP (1) EP0988056B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002514201A (cg-RX-API-DMAC7.html)
KR (1) KR100565883B1 (cg-RX-API-DMAC7.html)
CN (1) CN100333796C (cg-RX-API-DMAC7.html)
AT (1) ATE244579T1 (cg-RX-API-DMAC7.html)
AU (1) AU735187C (cg-RX-API-DMAC7.html)
BR (1) BR9806793A (cg-RX-API-DMAC7.html)
CA (1) CA2278106C (cg-RX-API-DMAC7.html)
CY (1) CY2416B1 (cg-RX-API-DMAC7.html)
DE (1) DE69816297T9 (cg-RX-API-DMAC7.html)
ES (1) ES2197458T3 (cg-RX-API-DMAC7.html)
IL (1) IL130908A0 (cg-RX-API-DMAC7.html)
NO (1) NO323702B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ336720A (cg-RX-API-DMAC7.html)
PT (1) PT988056E (cg-RX-API-DMAC7.html)
WO (1) WO1998031394A2 (cg-RX-API-DMAC7.html)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
BR9806793A (pt) 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.
US20050260177A1 (en) * 1998-06-05 2005-11-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
RU2227752C2 (ru) * 1998-11-12 2004-04-27 Новолитикс Инк. Способы перекрытия кровотока и композиции для их реализации
DE60040981D1 (de) * 1999-05-14 2009-01-15 Genentech Inc BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US20030103948A1 (en) * 1999-06-07 2003-06-05 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
CA2377381C (en) * 1999-07-01 2013-06-11 Yale University Neovascular-targeted immunoconjugates
US6693176B1 (en) * 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
EP1204682B1 (en) * 1999-07-28 2010-11-17 Genentech, Inc. Compositions and methods for the treatment of tumors
US7217554B2 (en) 1999-08-31 2007-05-15 Novozymes A/S Proteases and variants thereof
AU6820000A (en) * 1999-08-31 2001-03-26 Novozymes A/S Novel proteases and variants thereof
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
CN109395082A (zh) 2000-05-19 2019-03-01 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
TWI317285B (en) * 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
CN101486761A (zh) 2000-09-13 2009-07-22 诺沃挪第克健康护理股份公司 人凝血因子vii变体
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
US7622437B2 (en) * 2000-11-20 2009-11-24 The Board Of Trustees Of The University Of Illinois Tissue factor compositions and methods
IL156690A0 (en) * 2000-12-29 2004-01-04 Savient Pharmaceuticals Inc Specific human antibodies for selective cancer therapy
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7132510B2 (en) 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
WO2003028840A2 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
DE60238435D1 (de) * 2001-10-26 2011-01-05 Scripps Research Inst Gezielte thrombose durch gewebefaktor polypeptiden
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
AU2002365162A1 (en) * 2001-11-14 2003-07-09 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
WO2003057252A1 (en) * 2002-01-03 2003-07-17 Tanox, Inc. Human mast cell-expressed membrane proteins
AU2003215280A1 (en) * 2002-02-15 2003-09-09 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
US20040102402A1 (en) * 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of tissue factor expression
WO2005014775A2 (en) * 2002-06-28 2005-02-17 University Of Florida Research Foundation, Inc. Raav compositions and methods for delivery of human factor vii polypeptides and treatment of hemophilia a
US20040208877A1 (en) * 2002-07-01 2004-10-21 Avigdor Levanon Antibodies and uses thereof
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
WO2004006847A2 (en) 2002-07-15 2004-01-22 Board Of Regents, The University Of Texas System Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
US7534761B1 (en) 2002-08-21 2009-05-19 North Western University Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
WO2004046167A2 (en) * 2002-11-14 2004-06-03 Northwestern University Synthesis and self-assembly of abc triblock bola peptide
US20040115204A1 (en) * 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
WO2004072104A2 (en) 2003-02-11 2004-08-26 Northwestern University Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
EP2085470B1 (en) * 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII or FVIIa variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004239244C1 (en) 2003-05-06 2015-04-23 Bioverativ Therapeutics Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
US20110002978A1 (en) 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
US20070207158A1 (en) * 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
EP1660658A2 (en) * 2003-08-06 2006-05-31 Hans Peter B. Prydz The use of sirna silencing in the prevention of metastasis
DE10338733A1 (de) * 2003-08-22 2005-03-24 Berdel, Wolfgang E., Prof. Dr.med. Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie
CN1863908B (zh) 2003-09-09 2010-08-04 诺和诺德医疗保健公司 凝固因子ⅶ多肽
KR20070004561A (ko) 2003-12-05 2007-01-09 노오쓰웨스턴 유니버시티 분지형 펩티드 친양매성 화합물들, 그들의 관련된 에피토프화합물들 및 자가조립된 구조들
WO2005056039A1 (en) * 2003-12-05 2005-06-23 Northwestern University Self-assembling peptide amphiphiles and related methods for growth factor delivery
DK2805728T3 (da) * 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
WO2005077333A2 (en) * 2004-02-10 2005-08-25 University Of Florida Research Foundation, Inc. Gel-based delivery of recombinant adeno-associated virus vectors
JP2007529542A (ja) * 2004-03-18 2007-10-25 セント・ルークス・ホスピタル 徐放性剤の送達方法
EP1761231A1 (en) * 2004-06-07 2007-03-14 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
WO2006047684A2 (en) * 2004-10-27 2006-05-04 The Board Of Trustees Of The University Of Illinois, Et Al. Tissue factor phospholipid vesicle particles and methods of use for coagulation
NZ560649A (en) * 2005-03-04 2011-03-31 Univ Northwestern Angiogenic heparin binding peptide amphiphiles, peptide amphiphiles, self-assembled composition and related methods of use
US7393833B2 (en) * 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8076295B2 (en) * 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
CA2718869C (en) 2008-03-19 2018-10-30 China Synthetic Rubber Corporation Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
WO2010089379A1 (en) * 2009-02-05 2010-08-12 Pierre Philippart Method and means for producing tissues and tissues obtained
AU2010236584A1 (en) * 2009-04-13 2011-11-10 Northwestern University Novel peptide-based scaffolds for cartilage regeneration and methods for their use
CN102153653B (zh) * 2010-12-30 2012-08-15 厦门大学 肿瘤血管靶向多肽与组织因子的融合蛋白及其制备方法
EP3044323B1 (en) 2013-09-13 2022-04-06 F. Hoffmann-La Roche AG Methods for detecting and quantifying host cell protein in cell lines
JP6751344B2 (ja) 2013-09-13 2020-09-02 ジェネンテック， インコーポレイテッド 精製された組み換えポリペプチドを含む方法及び組成物
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
CN104387474B (zh) * 2014-11-17 2018-01-23 北京华安科创生物技术有限公司 一种肿瘤血管梗塞剂多肽、基因、表达载体及其应用
CN106699875A (zh) * 2017-02-23 2017-05-24 青岛古高生物科技有限公司 一种人重组组织因子及其基因、表达载体、宿主菌和表达方法
WO2020032951A1 (en) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
CN108948209A (zh) * 2018-07-17 2018-12-07 广西医科大学 一种cd105单链抗体-es融合蛋白的制备方法和用途
CN109999182B (zh) * 2019-03-29 2023-03-07 四川大学华西医院 凝血因子在制备抗肿瘤药物中的应用
WO2025096770A1 (en) * 2023-10-31 2025-05-08 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3360633D1 (en) * 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
NZ221790A (en) 1986-09-12 1990-07-26 Genentech Inc Method for the continuous production of a heterologous protein in a eukaryotic host cell
US5017556A (en) * 1986-11-04 1991-05-21 Genentech, Inc. Treatment of bleeding disorders using lipid-free tissue factor protein
DE3751218T2 (de) 1986-11-04 1995-11-09 Genentech Inc Verfahren und therapeutische Zubereitungen für die Behandlung von Gerinnungsstörungen.
US5589173A (en) * 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US6001978A (en) 1987-03-31 1999-12-14 The Scripps Research Institute Human tissue factor related DNA segments polypeptides and antibodies
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5472850A (en) 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
WO1994005328A1 (en) * 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
WO1994007515A1 (en) * 1992-10-06 1994-04-14 The Scripps Research Institute Mutant tissue factor lacking factor vii activation activity
JP3398382B2 (ja) 1992-10-28 2003-04-21 ジェネンテク，インコーポレイテッド 血管内皮細胞増殖因子アンタゴニスト
US5726147A (en) * 1993-06-01 1998-03-10 The Scripps Research Institute Human mutant tissue factor compositions useful as tissue factor antagonists
US5830448A (en) 1994-06-16 1998-11-03 Genentech, Inc. Compositions and methods for the treatment of tumors
NZ288883A (en) * 1994-07-11 1998-12-23 Univ Texas Conjugates comprising coagulation factors
US5583267B1 (en) * 1995-01-27 1998-11-24 Enzymol International Biocatalytic process for preparing tetraalkylbiphenols
US5922688A (en) 1997-01-10 1999-07-13 Board Of Regents, The University Of Texas System PEA3 is a tumor suppressor
BR9806793A (pt) 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.
US6303596B1 (en) 1997-05-22 2001-10-16 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis

Also Published As

Publication number Publication date
US7101557B2 (en) 2006-09-05
CY2416B1 (en) 2004-11-12
NO323702B1 (no) 2007-06-25
CA2278106C (en) 2005-04-12
NO993567L (no) 1999-09-21
DE69816297T9 (de) 2004-09-09
NZ336720A (en) 2001-06-29
US20030232753A1 (en) 2003-12-18
IL130908A0 (en) 2001-01-28
US7951356B1 (en) 2011-05-31
KR100565883B1 (ko) 2006-03-31
KR20000070389A (ko) 2000-11-25
CN1251532A (zh) 2000-04-26
US6132730A (en) 2000-10-17
AU5924398A (en) 1998-08-07
EP0988056A2 (en) 2000-03-29
PT988056E (pt) 2003-09-30
DE69816297D1 (de) 2003-08-14
CA2278106A1 (en) 1998-07-23
US6132729A (en) 2000-10-17
DE69816297T2 (de) 2003-12-24
EP0988056B1 (en) 2003-07-09
CN100333796C (zh) 2007-08-29
ATE244579T1 (de) 2003-07-15
NO993567D0 (no) 1999-07-21
WO1998031394A3 (en) 1998-09-17
ES2197458T3 (es) 2004-01-01
WO1998031394A2 (en) 1998-07-23
AU735187C (en) 2002-04-18
JP2002514201A (ja) 2002-05-14
AU735187B2 (en) 2001-07-05
US6156321A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
BR9806793A (pt) Processos e composições de fator tissular para coagulação e tratamento de tumores.
DE60118172D1 (de) Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
CY1109614T1 (el) Μορια παρομοια με παραγοντα vii ή viia
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
IL140700A0 (en) Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
HUP0102039A2 (hu) Albuminnal stabilizált paclitaxel alkalmazása tömör tumorok kezelésére szolgáló gyógyszerkészítmények előállítására, és a kapott gyógyszerkészítmények
PL350658A1 (en) Medical preparations for the treatment of alpha−galactosidase a deficiency
ATE328599T1 (de) Antitumorale mittel
CY1110113T1 (el) Φωσφολιπιδιου παραγωγα βαλπροϊκου οξεος και μειγματα αυτων
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
BR9810520A (pt) Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial
AU2001264515A1 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
BRPI0516265A (pt) composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente
EP1545479A4 (en) EZETIMIB COMPOSITIONS AND METHOD FOR THE TREATMENT OF CHOLESTERIN-ASSOCIATED GOOD AND EVIL TUMORS
ES2195655T3 (es) Procedimiento para tratar fiebre hemorragica virica con proteina c.
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
EA200301295A1 (ru) Полипептид, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
TR200000890T2 (tr) Topik ilacın üretilmesi için -amino levülozik asidin kullanılması
ID28035A (id) Kegunaan turunan antrasiklin untuk pengobatan tumor hati

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/68 (2017.01), A61K 47/64 (2017.0